Skip to main content

Table 2 Outcomes/outcome measures used in the feasibility study

From: The Care Home Independent Prescribing Pharmacist Study (CHIPPS)—a non-randomised feasibility study of independent pharmacist prescribing in care homes

 • STOPP/START (medication appropriateness tool) [17]

 • Drug burden index [18]

 • Fall rate per patient as per standard care home safety data collection

 • Adverse drug events as would normally be reported by a care home

 • Mortality

 • Barthel Index (physical functioning) [19]

 • Mini Mental State Examination (MMSE) (Cognitive functioning) [20]

 • Qualidem [21] (dementia specific quality of life)

 • EuroQoL EQ-5D-5 L [2] (Proxy version 1). The proxy (care home staff, key worker) was asked to rate how he or she (i.e. the proxy), would rate the subject’s health (quality of life) [22]

 • EuroQol EQ-5D-5 L face-to-face with resident (quality of life) [22]